US Stem Cell Inc (USRM)

[Bayflynn]

Some Good Points From The Article

1. According to BCC Research, the global stem cell market is expected to grow to over $10B in 2018. Additionally, according to Mordor Intelligence, the global market for stem cells was estimated to be $12B in 2016, and the firm projects the market to reach $26.6B by 2021. That said, if US Stem Cell Inc (OTCMKTS:USRM) executes properly, it could tap into that market.

2. Getting back to company news. US Stem Cell Inc recently announced it was working closely with the FDA, and applied for regenerative advanced therapy (RAT) designation, from the U.S. Food and Drug Administration (FDA). After the passing of the 21st Century Cures Act US Stem Cell Inc applied to the FDA for the Regenerative Advanced Therapy Design (RAT) Designation.

3. The FDA requested additional information for the MARVEL Phase II and III trial, and US Stem Cell provided all the information to the U.S. FDA, and the company is hopeful that the administration would continue its review of the company’s MyoCell product.

4. According to US Stem Cell, the “REGROW component of the Cures Act, the FDA will grant RAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease. We believe that our MyoCell product meets these requirements, as we have demonstrated clinical efficacy in both preclinical and clinical studies, including our most recent MARVEL trial publication.”

5. US Stem Cell developed a strategic alliance with Advanced Stem Cell Rx (ASC), recently. Advanced Stem Cell Rx is a U.S.-based provider of regenerative medicine programs.

6. Dr J.S. Landow, Managing Director of ASC, stated “Stem cells are critical to our survival and at the core of our regenerative and healing powers. They will play an immense role in redefining the preferred treatment method for the majority of diseases commonly afflicting mankind. We, at ASC, are proud to form a strong alliance with US Stem Cell Inc., one of the oldest and most respected stem cell research and therapy companies in the world.”

7.The recent developments in US Stem Cell and the projected growth rates in the industry could potentially drive USRM higher. Now, if you haven’t had this on your watch list, it might be worth considering.